Diffuse intrinsic brain stem glioma in children: Current treatment and future directions;Gliomes infiltrants du tronc cérébral chez l'enfant : traitement actuel et perspectives

Archives de Pediatrie

Volumn 17, Issue 2, 2010, Pages 159-165

  Leblond, P ^a   Vinchon, M ^b   Bernier Chastagner, V ^c   Chastagner, P ^d  

^a CENTRE OSCAR LAMBRET   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CENTRE ALEXIS VAUTRIN   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CELECOXIB; CILENGITIDE; CISPLATIN; CYTOTOXIC AGENT; ERLOTINIB; ETANIDAZOLE; ETOPOSIDE; GEFITINIB; IMATINIB; IRINOTECAN; LENALIDOMIDE; METHOTREXATE; PACLITAXEL; RETINOIC ACID; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; TROFOSFAMIDE; VANDETANIB; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BRAIN BIOPSY; BRAIN STEM TUMOR; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIAGNOSTIC VALUE; DOSE RESPONSE; GLIOBLASTOMA; GLIOMA; HUMAN; MEDULLOBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; SHORT SURVEY;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRAIN STEM NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; GLIOMA; HUMANS; PROGNOSIS; RADIOTHERAPY, ADJUVANT;

EID: 74449089307     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2009.11.016     Document Type: Short Survey

References (54)

1. Terracini B., Coebergh J.W., Gatta G., et al. Childhood cancer survival in Europe: an overview. Eur J Cancer s37 (2001) 810-816
2. Epstein F.J., and Farmer J.P. Brain-stem glioma growth patterns. J Neurosurg 78 (1993) 408-412
3. Schumacher M., Schulte-Mönting J., Stoeter P., et al. Magnetic resonance imaging compared with biopsy in the diagnosis of brainstem diseases of childhood: a multicenter review. J Neurosurg 106 (2007) 111-119
4. Thakur S.B., Karimi S., Dunkel I.J., et al. Longitudinal MR spectroscopic imaging of pediatric diffuse pontine tumors to assess tumor aggression and progression. Am J Neuroradiol 27 (2006) 806-809
5. Porto L., Hattingen E., Pilatus U., et al. Proton magnetic resonance spectroscopy in childhood brainstem lesions. Childs Nerv Syst 23 (2007) 305-314
6. Roujeau T., Machado G., Garnett M.R., et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg 107 1 Suppl. (2007) 1-4
7. Klein O., Chastagner P., Joud A., et al. Pontine tumors. J Neurosurg Pediatrics 1 (2008) 423-424
8. Fouladi M., Hunt D.L., Pollack I.F., et al. Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without irradiation on Children's Cancer Group high-grade glioma study CCG-945. Cancer 98 (2003) 1243-1252
9. Chastagner P., Kalifa C., Doz F., et al. Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) pilot study. Pediatr Blood Cancer 49 (2007) 803-807
10. Wolff J.E., Gnekow A.K., Kortmann R.D., et al. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer 94 (2002) 264-271
11. Bucci M.K., Maity A., Janss A.J., et al. Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: results from a single center in the magnetic resonance imaging era. Cancer 101 (2004) 817-824
12. Packer R.J., Boyett J.M., Zimmerman R.A., et al. Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II trial. Cancer 74 (1994) 1827-1834
13. Janssens G.O., Gidding C.E., Van Lindert E.J., et al. The role of hypofractionation radiotherapy for diffuse intrinsic brainstem glioma in children: a pilot study. Int J Radiat Oncol Biol Phys 73 (2009) 722-726
14. Mandell L.R., Kadota R., Freeman C., et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 43 (1999) 959-964
15. Bernier-Chastagner V., Grill J., Doz F., et al. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas. Results of a French Society of Paediatric Oncology Phase II Study. Cancer 104 (2005) 2792-2797
16. Allen J., Siffert J., Donahue B., et al. A phase I/II study of carboplatine combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer 86 (1999) 1064-1069
17. Doz F., Neuenschwander S., Bouffet E., et al. Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Société française d'oncologie pédiatrique. Eur J Cancer 38 (2002) 815-819
18. Korones D.N., Fisher P.G., Kretschmar C., et al. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. Pediatr Blood Cancer 50 (2008) 227-230
19. De Aquino Gorayeb M.M., Aisen S., Nadalin W., et al. Treatment of childhood diffuse brain stem tumors: comparison of results in different treatment modalities. Clin Transl Oncol 8 (2006) 45-49
20. Broniscer A., Leite C.C., Lanchote V.L., et al. Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. J Clin Oncol 18 (2000) 1246-1253
21. Marcus K.J., Dutton S.C., Barnes P., et al. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys 55 (2003) 1182-1185
22. Wolff J.E., Westphal S., Molenkamp G., et al. Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer 87 (2002) 945-949
23. Liu L., Vapiwala N., Munoz L.K., et al. A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors. Med Pediatr Oncol 37 (2001) 390-392
24. Aquino-Parsons C., Hukin J., and Green A. Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas. Pediatr Blood Cancer 50 (2008) 397-399
25. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
26. Sirachainan N., Pakakasama S., Visudithbhan A., et al. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neuro Oncol 10 (2008) 577-582
27. Chastagner P., Bouffet E., Grill J., et al. What have we learnt from previous phase II trials to help in the management of childhood brain tumours?. Eur J Cancer 37 (2001) 1981-1993
28. Broniscer A., Iacono L., Chintagumpala M., et al. Role of temozolomide afetr radiotherapy for newly diagnosed diffuse brainstem glioma in children. Results of multi-institutional study (SJHG-98). Cancer 103 (2005) 133-139
29. Donson A.M., Addo-Yobo S.O., Handler M.H., et al. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48 (2007) 403-407
30. Ohno M., Natsume A., Fujii M., et al. Interferon-beta. MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma. Pediatr Blood Cancer 53 (2009) 37-41
31. Chintagumpala M.M., Friedman H.S., Stewart C.F., et al. A phase II window trial of procarbazine and topotecan in children with high grade glioma: a report from the children's oncology group. J Neurooncol 77 (2006) 193-198
32. Vredenburgh J.J., Desjardins A., Reardon D.A., et al. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol 11 (2009) 80-91
33. Frappaz D., Schell M., Thiesse P., et al. Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial. Neuro Oncol 10 (2008) 599-607
34. Haas-Kogan D.A., Banerjee A., Kocak M., et al. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol 10 (2008) 341-347
35. Fouladi M., Nicholson H.S., Zhou T., et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer 110 (2008) 2535-2541
36. Pollack I.F., Jakacki R.I., Blaney S.M., et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol 9 (2007) 145-160
37. Geoerger B, Hargrave D, Ndiaye A, et al. ITCC phase I study of erlotinib in children with refractory and relapsed malignant brain tumors and combined with irradiation in newly diagnosed brain stem glioma. SIOP 2007 Congress, Mumbai.
38. Jain R.K., Di Tomaso E., Duda D.G., et al. Angiogenesis in brain tumours. Nat Rev Neurosci 8 (2007) 610-622
39. Plate K.H., Breier G., Weich H.A., et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359 (1992) 845-848
40. André N., Pasquier E., Verschuur A., et al. Chimiothérapie métronomique en oncologie pédiatrique : effet de mode ou espoir réel ?. Arch Pediatr 16 (2009) 1158-1165
41. Pope W.B., Lai A., Nghiemphu P., et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66 (2006) 1258-1260
42. Vredenburgh J.J., Desjardins A., and Herndon II J.E. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13 (2007) 1253-1259
43. Chen W., Delaloye S., Silverman D.H., et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25 (2007) 4714-4721
44. Benesch M., Windelberg M., Sauseng W., et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 19 (2008) 807-813
45. Chatterjee S., Matsumura A., Schradermeier J., et al. Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol 46 (2000) 135-144
46. Taga T., Suzuki A., Gonzales-Gomes I., et al. Alpha v-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98 (2002) 690-697
47. Nabors L.B., Mikkelsen T., Rosenfeld S., et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25 (2007) 1651-1657
48. Reardon D.A., Fink K.L., Mikkelsen T., et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastome multiforme. J Clin Oncol 26 (2008) 5610-5617
49. MacDonald T.J., Stewart C.F., Kocak M., et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 26 (2008) 919-924
50. Mikkelsen T., Brodie C., Finniss S., et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124 (2009) 2719-2727
51. Hollingworth W., Medina L.S., Lenkinski R.E., et al. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol 27 (2006) 1404-1411
52. Cao Y., Tsien C.I., Nagesh V., et al. Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT. Int J Radiat Oncol Biol Phys 64 (2006) 876-885
53. Panigrahy A., Nelson M.D., Finlay J.L., et al. Metabolism of diffuse intrinsic brainstem gliomas in children. Neuro Oncol 10 (2008) 32-44
54. Charnley N., West C.M., Barnett C.M., et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 331-338